Carey E etal. Second Look at Utilization of a Closed-System Transfer Device (PhaSeal). Am J Pharm Benefits. 2011;3(6):311-316.
Connor T, Anderson R, Sessink P et al. Effectiveness of a dosed-system device in containing surface contamination with cyclophosphamide and ifosftamide inan IM. admixture area. Am J
Health Syst Pharm.2002; 59: 68-72.
Gustavsson B. Evaluation of technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract. 1997; 3:46.
Harrison B, Peters B, Bing M. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation
technigues. Am J Health Syst Pharm. 2006; 63: 1736-1744,
Jorgenson J, Spivey 5. Au C etal. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2005; 43(9): 723-727
Jorgenson J. Leakproof connection integrity testfor devices intended for handling hazardous drugs.(Presented at ASHP Midyear Clinical Meeting. December 2007.)
Jorgenson J. 2007 Utah protocol update: evaluation of vial transfer devices for containment of hazardous drug vapors. (Presented at ASHP Midyear Clinical Meeting. December 2007.)
McDiarmid M., Oliver M., Rogers B.. etal. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. JOEM. 2010; 52(10): 1028-1034.
McMichael D, Jefferson D, Carey E et al. Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits. 2011; 3(1): 9-16.
Nishigaki R, Konno E, Sugiyasu Metal. The usefulness of a closed-system device for the mixing of injections to prevent occupational exposure to anticancer drugs. Journal of Japanese Society
of Hospital Pharmacists. 2010; 46(1): 113-117.
Nyman H, Jorgenson |, Slawson M. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007; 42(3):219-
Sessink P Rolf M, Ryden 5. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm.1999: 34: 1311-1317.
Spivey 5, Connor T. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003;
Vandenbroucke J, Robays H. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. EJHP Practice. 2006; 14(5): 37-42.
Wick C, Slawson M, Jorgenson J et al. Using a closed-system protective device toreduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60: 2314-2320.